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http://dx.doi.org/10.1016/j.immuni.2015.04.006Over the last two decades, our ability to
interrogate the immune system on a sin-
gle-cell level has increased dramatically
(Chattopadhyay and Roederer, 2012;
Bendall et al., 2011), allowing an oppor-
tunity to better understand the immuno-
logical mechanisms underlying disease.
Complex flow cytometry (FCM) data are
now surpassing our ability to fully analyze
and interpret all information via current
standard approaches, such as 2D dot
plots and Boolean gates. Indeed, the
number of potential cell subpopulations
increases exponentially with the number
of parameters assessed, making it diffi-
cult to decipher all possible combina-
tions included in the raw data (e.g., 512
potential subsets with nine markers) via
the traditional approaches (Bendall and
Nolan, 2012). This could limit the transla-
tion of technical advances into new diag-
nostics or therapies. Newly developed
bioinformatics tools that have the poten-
tial to bridge this gap are now available.
The aim of this letter is to foster the
implementation and adoption of these
novel computational methodologies forunbiased analysis of complex cytometry
data.
In recent years, a host of new data-
analysis tools have emerged, creating
workflows for processing and analyzing
complex FCM datasets; however, these
have gone mostly unnoticed by immunol-
ogists. Table S1 provides an overview of
many of the currently available tools and
their specific applications. They can be
assigned to specific categories arranged
in a ‘‘FCM data-analysis workflow’’ from
compensated data as input to biologi-
cally interpretable results as output. The
vast majority of the listed tools for FCM
data processing, analysis, and visualiza-
tion are made available by the bio-
informaticians at no cost and include
open source code and unrestrictive soft-
ware licensing, opening up these compu-
tational approaches to broad use by the
research community. Many of the tools
have been developed to address similar
analysis objectives via quite different ap-
proaches. They might provide optimal re-
sults for different datasets, such that there
is no ‘‘right’’ or ‘‘best’’ tool, and usingImmunityseveral algorithms in combination might
yield even better results and exceed
the possibilities offered by manual anal-
ysis. Comprehensive comparative studies
by the Flow Cytometry: Critical Assess-
ment of Population IdentificationMethods
(FlowCAP) project have shown that many
of these tools have reached a level of
maturity that matches, or even surpasses,
the results produced by human experts
(Aghaeepour et al., 2013).
The development of computational ap-
proaches addresses many needs asso-
ciated with high-dimensional datasets.
However, for the immunology community,
three main challenges have surfaced, and
tackling them will facilitate a paradigm
shift in the analysis of FCM data. First,
despite the focused efforts by bio-
informaticians to develop novel tools for
analyzing FCM data, only a minority of im-
munologists are aware of the advantages
offered to the field. These tools need to be
presented in immunology forums rather
than limited to bioinformatics journals
and conferences. Second, even though
the vast majority of the computational42, April 21, 2015 ª2015 Elsevier Inc. 591
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available, most do not have user-friendly
interfaces, limiting their use to investiga-
tors with programming expertise. Third,
as a consequence of the first two chal-
lenges, there is a lack of general under-
standing of how these novel tools work.
This has two opposing effects. In some
cases, skepticism increases because of
a feeling that direct control of analysis
has been lost and that results are unverifi-
able. In other cases, overconfidence oc-
curs, and no real effort is made to validate
results. This can lead to the reporting of
‘‘significant’’ cell populations that actually
arise from experimental artifact (and
quality-control issues).
These are challenges that must be ad-
dressed, both in terms of generalizable
strategies and within each individual
experiment, with the goals of broader
adoption and more accurate results.
Inter-disciplinary collaborations be-
tween immunologists and bioinforma-
ticians might help address these points,
as demonstrated by pioneering collab-
orations that identified immunological
correlates of HIV protection in high-dimen-
sional FCMdata (Aghaeepour et al., 2012).
Such collaborations could also be imple-
mented within institutions and research
groups by convening bioinformaticians
and immunologists or by team members
trained in both immunology and bioinfor-
matics. Hence, inter-disciplinary collabo-
ration should be encouraged as soon as
a study is conceived and should continue
through the entire study (from wet bench
experimentation to final data analysis to
publication).592 Immunity 42, April 21, 2015 ª2015 ElsevAnother, possibly game-changing solu-
tion is to develop user-friendly web or
computer interfaces that would allow
immunologists with little bioinformatics
background to rationally combine the
available tools and run datasets through
different workflows to achieve optimal re-
sults. Work on making this model a reality
is ongoing. The FLOCK algorithm (Qian
et al., 2010) has been implemented in the
Immunology Database and Analysis Por-
tal (https://immport.niaid.nih.gov), which
supports management of FCM data, cell-
population identification, cross-sample
comparison, and result visualization with
a simple user interface. Also, a compre-
hensive suite of tools for processing and
analyzing FCM data has been imple-
mented within the GenePattern infra-
structure (Spidlen et al., 2013). Finally,
the OpenCyto framework provides open-
source tools for analyzing FCMdatawithin
an extensible and flexible interface to
simplify the construction of re-usable
FCM workflows while facilitating compar-
ative analysis against manually gated re-
sults in order to enhance user confidence
(Finak et al., 2014).
Progress in cytometry technology
generates complex datasets for which
exhaustive analysis by existing practices
is difficult. Solutions for deciphering
multi-dimensional FCM and mass cytom-
etry datasets exist but have not yet
reached most immunologists. Here, we
describe a list of available computational
tools with the aim of enhancing aware-
ness, access, and acceptance and
discuss models to bridge the existing
gap between immunology and bioinfor-ier Inc.matics. We predict that interdisciplinary
efforts to address the current data-anal-
ysis bottlenecks will rapidly enhance our
knowledge of the immune system, guide
immunotherapy development, accel-
erate biomarker discovery, and ultimately
benefit patients.
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